Gene Editing

Vertex Pharmaceuticals Inc (NASDAQ: VRTX) and Arbor Biotechnologies have announced a new collaboration to develop ex vivo engineered cell therapies. The new agreement between Arbor and Vertex builds upon the companies' first partnership established in 2018.  Related:...

Editas Medicine Inc (NASDAQ: EDIT) announced data on a new gene-editing technology termed SLEEK (SeLection by Essential-gene Exon Knock-in).  Data were presented at the Cold Spring Harbor Laboratory's Genome Engineering: CRISPR Frontiers meeting. Editas' SLEEK platform...

A differentiated approach to gene editing has ushered a bullish sentiment from BofA Securities and Morgan Stanley on Graphite Bio, Inc. (NASDAQ: GRPH) just a few weeks after its IPO. BofA Securities on Graphite Bio Analyst Geoff Meacham initiated the firm’s coverage on Graphite with a...

Tenaya Therapeutics (NASDAQ: TNYA) is quickstepping into a $100 million NASDAQ debut under the TNYA symbol. The company filed an SEC prospectus on Friday. The biotech firm is attacking heart disease through three different angles - gene therapy, cellular regeneration, and precision...

A World Health Organization expert advisory panel Monday issued two new reports recommending the implementation of global standards to prevent future unsafe or unethical uses of CRISPR and other gene-editing technologies. The panel was convened in December 2018 when a Chinese scientist...

Beam Therapeutics Inc (NASDAQ: BEAM) joins forces with Apellis Pharmaceuticals Inc (NASDAQ: APLS) to create new gene-editing treatments for complement-driven diseases. The partnership will leverage Beam’s base-editing technology to discover new treatments against various...

Gene-editing technology CRISPR reached a significant milestone this week, completing its first systemic delivery as a medicine to the human body. What Happened: On Monday, Intellia Therapeutics Inc (NASDAQ: NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) ...

Intellia Therapeutics Inc (NASDAQ: NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have announced positive interim data from an ongoing Phase 1 study of NTLA-2001, which is being developed as a single-dose treatment for transthyretin (ATTR) amyloidosis. Interim...

Qiagen NV (NYSE: QGEN) has launched dedicated solutions specific to CRISPR technology used for editing genomes and modifying gene function. QiaPrep&Amp CRISPR Kit and Q-Primer Solutions expand Qiagen portfolio for CRISPR applications. The solutions allow researchers to analyze...

Precision BioSciences Inc (NASDAQ: DTIL) has announced new in vivo data using ARCUS genome editing platform resulting from a preclinical research collaboration with investigators at the University of Pennsylvania. Data were presented at the 2021 American Society of Genetic...

The Chinese scientist who created the world’s first “gene-edited” babies was sentenced to three years in prison in China on Monday, according to Reuters.  What Happened A Chinese court sentenced scientist He Jiankui to three years in prison and fined him in the...

Crispr Therapeutics AG (NASDAQ: CRSP) shares are ripping higher after the company focused on developing gene therapies using its proprietary CRISPR/Cas9 platform said CTX001, a gene-editing therapy it's co-developing with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), produced positive...

Intellia Therapeutics Inc’s (NASDAQ: NTLA) gene editing drug seems to have the potential to disrupt the treatment of hereditary transthyretin amyloidosis, according to Baird. The Analyst Madhu Kumar initiated coverage of Intellia Therapeutics with an Outperform rating and $23 price target....